PBPH
Portfolio Building Block World Pharma and Biotech Index ETF
The Portfolio Building Block World Pharma and Biotech Index ETF seeks to provide investors with exposure to a diversified portfolio of companies in the global pharmaceutical and biotechnology sectors, aiming for long-term capital appreciation.
Global
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 1.0 B
ASSETS UNDER MGMT
13 bp
EXPENSES
Fund Basics
| Inception date | Nov 25, 2025 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Monthly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| ELI LILLY & CO | 15.5 % |
| JOHNSON & JOHNSON | 10.0 % |
| ABBVIE INC | 7.2 % |
| MERCK & CO. INC. | 5.7 % |
| ASTRAZENECA PLC | 4.7 % |
| ROCHE HOLDING AG ORDINARY SHARES NEW | 4.6 % |
| AMGEN INC | 4.4 % |
| NOVARTIS AG | 4.2 % |
| GILEAD SCIENCES INC | 4.0 % |
| PFIZER INC | 3.5 % |
Constituent Breakdown
| Number of holdings | 56 |
| Herfindahl-Hirschman Index | 0 |
| Wgt avg mkt cap (mns) | $0 |
| Large cap (>$10bn) | 11.8% |
| Mid cap ($2-10bn) | 0.0% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 11.8% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 67.3 % |
 |
BRITAIN | 7.6 % |
 |
SWITZERLAND | 5.3 % |
 |
JAPAN | 3.7 % |
 |
DENMARK | 3.1 % |
 |
FRANCE | 1.9 % |
 |
GERMANY | 1.6 % |
 |
AUSTRALIA | 1.3 % |
 |
NETHERLANDS | 1.3 % |
 |
ISRAEL | 1.0 % |
Historical Performance
Standardized Performance (as of 09/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 12.5% | -- | -- | -- | -- | -- | -- | 13.2% |
| Dividend Yield | 0.0% | -- | -- | -- | -- | -- | -- | 0.1% |
| Total Returns | 12.5% | -- | -- | -- | -- | -- | -- | 13.3% | Ann. Volatility | 18.9% | -- | -- | -- | -- | -- | -- | 18.3% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.00 | 0% |
| MSCI EAFE | 0.00 | 0% |
| MSCI Emg Mkts | 0.00 | 0% |
Liquidity Measures
| Avg. volume (000) | 94 |
| ADV traded (mns) | $3 |
| Turnover | 0.3% |
| Avg. Bid/Ask (% of price) | 0.08% |
Technical Indicators
| 30d moving avg. (EMA) | $27.34 |
| Relative strength (RSI) | 56 |
| MACD/Signal | 0.28/0.26 |
| Bollinger Bands (Upper/Lower) | $28.36/$26.62 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. PBPH |
Expenses vs. PBPH |
ALTAR Score™ vs. PBPH |
|---|---|---|---|---|
| IYH | iShares U.S. Healthcare ETF | 60.2% | +27 bp | -0.7% |
| IXJ | iShares Global Healthcare ETF | 58.7% | +29 bp | -0.2% |
| XLV | Health Care Select Sector SPDR | 56.2% | -5 bp | +0.0% |
| FHLC | Fidelity MSCI Health Care Index ETF | 53.1% | -5 bp | -1.2% |
| VHT | Vanguard Health Care ETF | 52.3% | -4 bp | -1.4% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 51.9% | +47 bp | -0.4% |
| MEDX | Horizon Kinetics Medical ETF | 51.8% | +72 bp | -5.2% |
| JDOC | JPMorgan Healthcare Leaders ETF | 50.7% | +52 bp | -1.7% |
| HRTS | Tema Heart & Health ETF | 45.5% | +62 bp | -3.7% |
| THNR | Amplify Weight Loss Drug & Treatment ETF | 40.2% | +46 bp | -1.8% |
Risk and Returns: PBPH vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 10/13/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
6.4%
ALTAR SCORE™
75th
PERCENTILE
OVERWEIGHT
ETFRC RATING
There are 736 funds in the Global Equity category with an average
ALTAR Score™ of 4.6% and a standard deviation
of 2.7%. PBPH's ALTAR Score™ is approximately 0.7 standard
deviations above the category average. This places PBPH in the 75th percentile
among funds in the category.
Sell-Side Consensus
$
PRICE TARGET
-100.0%
UPSIDE